Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 06 2022 - 8:20AM
Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage
biotechnology company that is focusing on building high fidelity,
3D tissues that recapitulate key aspects of human disease, today
announced that Keith Murphy, Executive Chairman, will participate
in the H.C. Wainwright 24th Annual Global Investment Conference,
September 12 - 14, 2022.
Organovo plans to advance drugs discovered in
its cutting-edge human 3D disease models in inflammatory bowel
disease. In November 2021, the company guided that it expected to
establish its first such model in 2022. In May 2022, the company
announced that it had done so, successfully achieving a 3D tissue
model for Crohn’s Disease. Organovo expects to begin medicinal
chemistry on a lead program for Crohn’s Disease in the first half
of 2023.
Mr. Murphy will deliver the Organovo corporate
presentation and meet with investment community members during the
hybrid conference.
Event: |
H.C.
Wainwright 24th Annual Global Investment Conference |
|
September 12 - 14, 2022 |
|
|
Presentation Webcast: |
Monday, September 12, 2022, 7:00 AM ET |
The corporate presentation will be webcast on the Investors
section of the Organovo website at ir.organovo.com. Interested
parties can access an archived version of the presentation on the
company’s website for approximately 90 days.
About Organovo
Organovo is an early-stage biotechnology company
that is developing and utilizing highly customized 3D human tissues
as dynamic models of healthy and diseased human biology for drug
development. The company’s proprietary technology is being used to
build functional 3D human tissues that mimic key aspects of native
human tissue composition, architecture, function and disease.
Organovo’s advances include cell type-specific compartments,
prevalent intercellular tight junctions, and the formation of
microvascular structures. Management believes these attributes can
enable critical complex, multicellular disease models that can be
used to develop clinically effective drugs for selected therapeutic
areas. For more information visit Organovo's
website at www.organovo.com.
Forward Looking Statements
Any statements contained in this press release
that do not describe historical facts constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations, but are subject
to a number of risks and uncertainties. These risks and
uncertainties and other factors are identified and described in
more detail in the Company’s filings with the SEC, including
its Annual Report on Form 10-K filed with
the SEC on June 10, 2022, as such risk factors are
updated in its most recently filed Quarterly Report on Form 10-Q
filed with the SEC on August 11, 2022. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that the Company may issue in the future. Except as required by
applicable law, including the securities laws of the United
States, the Company does not intend to update any of the
forward-looking statements to conform these statements to reflect
actual results, later events or circumstances or to reflect the
occurrence of unanticipated events.
Investor Contact
Amato and Partners, LLCInvestor Relations
Counseladmin@amatoandpartners.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From May 2024 to Jun 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Jun 2023 to Jun 2024